The data underlying this study are available in the paper and its supporting information files. For any inquiries regarding the data, interested researchers may email the following address: <lifen_chen@163.com>.

Introduction {#sec001}
============

Cortical dysplasia is a common cause of epilepsy and accounts for at least 14% of epilepsy cases \[[@pone.0172214.ref001]\], among whom more than 40% were refractory epilepsy \[[@pone.0172214.ref002]\]. It happens mostly in childhood \[[@pone.0172214.ref003]\]. Although previous researches revealed several genetic and acquired causes of childhood cortical dysplasia (CCD) and the mechanisms of its epileptogenesis \[[@pone.0172214.ref004]\], our understanding of molecular mechanisms and pathogenesis underlying CCD with epilepsy is still limited.

In previous studies, only a few analyzed the proteomics of epilepsy patients using brain tissues or cerebrospinal fluid \[[@pone.0172214.ref005], [@pone.0172214.ref006], [@pone.0172214.ref007]\]. However, the proteomics or transcriptomics of CCD with epilepsy has not been analyzed, especially in brain tissues of CCD patients. Isobaric tags for relative and absolute quantitation (iTRAQ) is a comparative proteomic approach that can analyze up to 8 samples in one experiment, and is widely used in proteomic researches in different diseases \[[@pone.0172214.ref008], [@pone.0172214.ref009]\]. Moreover, This study screened the differentially expressed proteins in brain tissues of CCD patients with epilepsy compared to traumatic intracranial hypertension (TIH) patients using iTRAQ-based tandem mass spectrometry and selected several proteins that are differentially expressed or unreported associated with CCD previously for validation using real-time quantitative polymerase chain reaction (qPCR) analysis, immunoblotting and immunohistochemistry. Our result suggests that 153 out of 3340 proteins were diffrentially expressed in patients with CCD compared to controls, and these proteins are mainly involved in mechanisms of catalytic activity, binding, molecule-structuring activity, transporter activity, and enzyme regulation activity. Among these 153 proteins, 8 proteins that have not been associated with CCD, but participate in CCD-related biological processes or have CCD-related molecular functions according to Gene Oncology, including NDRG1, FSCN1, FABP3, DPYSL5, PSAP, MAP4, CRMP1, and PRDX6 were selected and validated.

Materials and methods {#sec002}
=====================

Patients and tissue preparation {#sec003}
-------------------------------

The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University (2013--026), and the study was conducted according to the principle expressed in the Declaration of Helsinki. Written consents were obtained from patients and/or their legal guardians. No author but S. L. and H. Y. had access to information that could identify individual participants during data collection, while no author had access to such information after data collection.

All the included CCD patients were recruited from 2013 August to 2014 December, and were preoperatively assessed with detailed history, neurological examination, neuropsychological test, ictal and interictal electroencephalography and MRI together with intraoperative electrocorticography for diagnosis and localization of lesions. After surgery, brain tissues from CCD patients were diagnosed by neuropathologists according to consensus of International League Against Epilepsy \[[@pone.0172214.ref010]\]. All included TIH patients underwent surgery had no history of neurological diseases, and the resected brain tissues were histologically normal. The resected tissues were immediately immersed into liquid nitrogen and strored at -80°C. Brain tissues of sex- and age-matched 8 CCD patients and 8 controls were selected for iTRAQ, brain tissues from the rest 15 CCD patients and 15 controls were used for qPCR, immunoblotting and immunohistochemistry.

Sample preparation and iTRAQ reagents labeling {#sec004}
----------------------------------------------

Total proteins were extracted with iTRAQ lysis buffer. The concentration of proteins was measured using 2-D Quant Kit (Amersham Biosciences, Uppsala, Sweden). Equal amount of proteins from each group were mixed. The pooled samples were subjected to iTRAQ labeling according to the iTRAQ kit protocol (Applied Biosystems, Framingham, MA, USA). Briefly, 2 μl reducing reagent was added to 200 μg protein and centrifuged, then it was incubated at 37°C for 1 hour. 1 μl of Cysteine-Blocking Reagent was added for cysteine blocking. Each protein sample was digested into peptide with 4 μg Trypsin overnight at 37°C. iTRAQ reagents were dissolved in isopropanol, and then mixed with the corresponding sample followed by incubation at room temperature for 3 hours. Samples from CCD patients were labeled with 118 tag and 121 tag, and samples from controls were labeled with 117 tag and 119 tag. All the iTRAQ reagent-labeled samples were then combined. \[[@pone.0172214.ref011], [@pone.0172214.ref012]\]

Peptide fractionation with Isoelectric Focusing (IEF) {#sec005}
-----------------------------------------------------

The labeled peptides samples were fractionated by IEF on immobilized pH gradient as described previously \[[@pone.0172214.ref013]--[@pone.0172214.ref015]\]. Briefly, the labeled peptides were dissolved in urea and Pharmalyte solution, applied to IPG strips (pH 3--10), and then focused with an IPGphor system (GE Healthcare Life Sciences Amersham Biosciences, Pittsburg, PA, USA) at 68 kVh. The IPG strips were cut into 36 pieces (0.5cm per piece). Peptides in each pieces was extracted with 0.1% formic acid and 2% acetonitrile and lyophilized and desalted with a C18 Discovery DSC-18 SPE column (Sigma-Aldrich). The desalted peptides were lyophilized again and stored at -20°C for mass spectrometry analysis.

Mass spectrometry and gene oncology analysis {#sec006}
--------------------------------------------

Mass spectrometry was performed with liquid chromatography coupled inline to a QStar mass spectrometer (Applied Biosystems, Framingham. MA, USA). Desalted peptides were reconstituted in a solution containing 0.1% formic acid and 2% acetonitrile, half of which was delivered into a trap column by an online capillary liquid chromatography system (Dionex Ultimate 3000, Amsterdam, The Netherlands). The peptide mixture were automatically separated on a C18-PepMap column (ThermoFisher Dionnex, Sunnyvale, CA, USA) at 0.3 μl/min. The eluent was analysed by OStar Elite Hybrid ESI Quadrupole time-of-flight tandem mass spectrometer (Applied Biosystems, Framingham. MA, USA) in an information-dependent acquisition mode. Mass spectrometer data acquisition was performed in the positive ion mode, with a selected mass range of 300--1800 *m/z*. A setting of 2 s was used as the total time for MS/MS events. The two charged peptides which were most abundant, with more than 20 counts, were selected for MS/MS and dynamically excluded for 30 s with ± 50 mDa mass tolerance.

Peptide identification and quantification was performed by ProteinPilot software (Applied Biosystems, Framingham, MA, USA). The search was performed using the International Protein Index (IPI) human database v3.87. Cysteine modification by MMTS was specified as a fixed modification \[[@pone.0172214.ref016]\].

For protein identification, a generally accepted standard which has been widely used in identifying and quantifying proteins with iTRAQ was taken \[[@pone.0172214.ref017]--[@pone.0172214.ref020]\]. The protein threshold was set to achieve 95% confidence, False discovery rate (FDR) statistics and 1.3-fold change cut-offs were used to classify the protein expressions as up-regulated (FDR\<0.05 and iTRAQ fold-changes above 1.3) or down-regulated (FDR\<0.05 iTRAQ and fold-changes below 0.77). For technical variation, while an analysis of repeated iTRAQ experiments established the technical variability to be not more than 30%. The gene oncology of each differentially expressed proteins was searched and classified using PANTHER classification system ([www.pantherdb.org](http://www.pantherdb.org/)). 8 differentially expressed proteins which have not been reported associated with CCD, but may participate in CCD-related biological processes or have CCD-related molecular functions according to previous literature were selected for further validation.

Real-time qPCR analysis {#sec007}
-----------------------

Total RNA was extracted using Trizol (Thermofisher, Waltham, USA). Extracted RNA was reverse transcribed into cDNA by A3500 Reverse Transcription System (Promega, Madison, WI, USA). qPCR was performed using TaqMan GeneExpression Kit in ABI 7900HT system. The sequences of primers (OriGene Technologies, Inc. Rockville, USA) were NDRG1 (HP209104), FSCN1 (HP206673), FABP3 (HP207465), DPYSL5 (HP213501), CRMP1 (HP232913), PRDX6 (HP208150), PSAP (HP231407), MAP4 (HP206072), and β-Actin (HP204660). The mRNA expression level were analyzed using ΔΔCt method.

Immunoblotting analysis {#sec008}
-----------------------

Total proteins were extracted with RIPA Lysis Buffer and the concentrations were determined with BCA Kit (Beyotime, Haimen, China). Protein samples were loaded to 10% SDS-PAGE gel for electrophoresis and transferred to PVDF membranes. The membranes were incubated in 0.4% gelatin for 1 hour at room temperature and then incubated in primary antibodies (CRMP1, DPYSL5, FSCN1, NDRG1, PRDX6) (1:1000--1:10000 dilution, Abcam, Cambridge, UK) at 4°C overnight. After washed with TBST buffer, the membranes were incubated in HRP-conjugated secondary antibody (1:5000 dilution) for 1h at room temperature. The protein bands were visualized using ECL detection system (Millipore, Germany) and analyzed using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).

Immunohistochemistry {#sec009}
--------------------

Brain tissues from CCD patients and controls were fixed with 4% paraformaldehyde overnight at 4°C, then routinely embedded in paraffin and sectioned. After dewaxing and rehydration, the sections were boiled in citrate buffer (pH 6.0) in microwave oven for 20 min for antigen retrieval. Endogenous peroxidase activity was quenched by treatment with 3% H~2~O~2~ for 10 min. The sections were blocked with goat serum for 30 min and incubated at 4oC overnight with primary antibodies (CRMP1 1:250, DPYSL5 1:100 and FSCN1 1:250). Then sections were incubated in goat-anti-rabbit secondary antibodies (30 min, 37°C) and visualized using DAB (ZSGB-Bio, Beijing, China). After counterstain with hematoxylin and dehydrated, sections were evaluated under microscope. A semi-quantitative score was applied to the images obtained from the microscope inspection. The staining intensity ranged from 1 to 3 and the percentage of positive cells was measured manually in a range from 0 to 100%. Staining intensity (1--3) was multiplied by the percentage of positive cells (0--100) to obtain a final score ranging from 0 to 300 \[[@pone.0172214.ref021]\]. This method was repeated three times for the immunohistochemistry of each antibody in the brain tissue samples.

Statistical analysis {#sec010}
--------------------

Data was expressed as mean±SD, FDR statistics was used to identified differentially expressed proteins, FDR\<0.05 was considered statistically significant. Intergroup differences in immunoblotting and immunohistochemistry between the CCD group and the control group were analyzed using t test or rank sum test. p\<0.05 was considered statistically significant.

Results {#sec011}
=======

Demographics and clinical characters of patients {#sec012}
------------------------------------------------

23 CCD patients (11 female, age 6.96±3.70, disease course 2.76±1.61 years) and 23 TIH patients (8 Female, age 7.22±3.10 years) who underwent surgery were included in this study. ([Table 1](#pone.0172214.t001){ref-type="table"})

10.1371/journal.pone.0172214.t001

###### Patient demographics and clinical characteristics.

![](pone.0172214.t001){#pone.0172214.t001g}

  Characteristic          CCD group            Controls
  ----------------------- -------------------- -----------
  Age (year), mean ± SD   6.96±3.70            7.22±3.10
  Sex (male/female)       12/11                15/8
  Diagnosis               CCD with epilepsy    Trauma
  Tissue pathology        Cortical dysplasia   Normal
  Resection tissue        Neocortex            Neocortex

CCD, Childhood cortical dysplasia.

Differentially expressed proteins revealed by iTRAQ analysis {#sec013}
------------------------------------------------------------

Brain tissues of 16 randomly selected patients (n = 8 for each group) were analyzed with iTRAQ. In total, 3440 proteins were found with 95% confidence, among which 153 proteins were differentially expressed (FDR\<0.05), including 64 up-regulated and 89 down-regulated proteins (Tables [2](#pone.0172214.t002){ref-type="table"} & [3](#pone.0172214.t003){ref-type="table"}).

10.1371/journal.pone.0172214.t002

###### 64 up-regulated proteins in childhood cortical dysplasia patients with epilepsy compared to controls by iTRAQ.

![](pone.0172214.t002){#pone.0172214.t002g}

  Accession           Gene Name   Protein                                                                             118:117   121:119
  ------------------- ----------- ----------------------------------------------------------------------------------- --------- ---------
  IPI:IPI00478003.3   A2M         Alpha-2-macroglobulin                                                               6.607     6.546
  IPI:IPI00335509.3   DPYSL5      Dihydropyrimidinase-related protein 5                                               5.152     4.966
  IPI:IPI00215801.1   RBM39       Isoform 2 of RNA-binding protein 39                                                 4.966     4.246
  IPI:IPI00291932.1   ACAN        Isoform 3 of Aggrecan core protein                                                  3.311     3.698
  IPI:IPI00923597.2   NDRG1       cDNA FLJ39243 fis, clone OCBBF2008283, highly similar to Protein NDRG1              3.631     3.597
  IPI:IPI00647915.1   TAGLN2      TAGLN2 24 kDa protein                                                               2.965     3.597
  IPI:IPI00218993.1   HSPH1       Isoform Beta of Heat shock protein 105 kDa                                          3.436     3.532
  IPI:IPI00220213.2   TNC         Isoform 4 of Tenascin                                                               3.342     3.404
  IPI:IPI00744780.2   BCAS1       Isoform 2 of Breast carcinoma-amplified sequence 1                                  3.767     3.311
  IPI:IPI00026237.1   MAG         Myelin-associated glycoprotein                                                      3.467     3.251
  IPI:IPI00640953.1   SIRT2       Sirtuin-2                                                                           3.221     2.992
  IPI:IPI00219684.3   FABP3       Fatty acid-binding protein, heart                                                   2.992     2.831
  IPI:IPI00641181.5   MARCKSL1    MARCKS-related protein                                                              2.704     2.831
  IPI:IPI00415014.3   MAP1LC3A    Isoform 1 of Microtubule-associated proteins 1A/1B light chain 3A                   3.221     2.729
  IPI:IPI00553211.1   ERMN        Isoform 2 of Ermin                                                                  2.729     2.704
  IPI:IPI00032958.3   ANLN        Isoform 2 of Actin-binding protein anillin                                          2.754     2.582
  IPI:IPI00298497.3   FGB         Fibrinogen beta chain                                                               2.630     2.559
  IPI:IPI00295777.6   GPD1        Glycerol-3-phosphate dehydrogenase \[NAD+\], cytoplasmic                            2.805     2.489
  IPI:IPI00556376.2   CRMP1       dihydropyrimidinase-related protein 1 isoform 1                                     2.630     2.489
  IPI:IPI00295469.5   CPNE6       cDNA FLJ55997, highly similar to Copine-6                                           2.399     2.270
  IPI:IPI00854567.3   KIAA1598    Isoform 2 of Shootin-1                                                              2.312     2.249
  IPI:IPI00022463.1   TF          Serotransferrin                                                                     2.270     2.249
  IPI:IPI00173346.3   PGM2L1      Glucose 1,6-bisphosphate synthase                                                   1.803     2.188
  IPI:IPI00059135.1   PPP1R14A    Isoform 1 of Protein phosphatase 1 regulatory subunit 14A                           2.606     2.148
  IPI:IPI00157414.3   ENPP6       Ectonucleotide pyrophosphatase/phosphodiesterase family member 6                    2.312     2.109
  IPI:IPI00396130.5   SRCIN1      Isoform 4 of SRC kinase signaling inhibitor 1                                       2.128     2.089
  IPI:IPI00856045.1   AHNAK2      Isoform 1 of Protein AHNAK2                                                         2.089     2.089
  IPI:IPI00329719.1   MYO1D       Myosin-Id                                                                           2.291     2.070
  IPI:IPI00007702.1   HSPA2       Heat shock-related 70 kDa protein 2                                                 2.070     2.070
  IPI:IPI00027223.2   IDH1        Isocitrate dehydrogenase \[NADP\] cytoplasmic                                       2.070     2.051
  IPI:IPI00747810.2   FSCN1       FSCN1 protein (Fragment)                                                            2.270     1.977
  IPI:IPI00940816.2   ARHGEF2     Isoform 3 of Rho guanine nucleotide exchange factor 2                               2.070     1.977
  IPI:IPI00021841.1   APOA1       Apolipoprotein A-I                                                                  2.089     1.905
  IPI:IPI00878314.1   MAP4        110 kDa protein                                                                     2.070     1.905
  IPI:IPI00553177.1   SERPINA1    Isoform 1 of Alpha-1-antitrypsin                                                    2.148     1.888
  IPI:IPI00029111.3   DPYSL3      Collapsin response mediator protein 4 long variant                                  1.941     1.871
  IPI:IPI00873622.3   WDR1        Putative uncharacterized protein WDR1                                               1.786     1.837
  IPI:IPI00045051.3   PURB        Transcriptional activator protein Pur-beta                                          1.941     1.803
  IPI:IPI00760925.2   MYO18A      Isoform 3 of Myosin-XVIIIa                                                          1.820     1.786
  IPI:IPI00554737.3   PPP2R1A     Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform   1.500     1.770
  IPI:IPI00004560.1   DCLK1       Isoform 2 of Serine/threonine-protein kinase DCLK1                                  1.854     1.706
  IPI:IPI00022388.2   DPYSL4      Dihydropyrimidinase-related protein 4                                               1.837     1.706
  IPI:IPI00304409.3   CARHSP1     Calcium-regulated heat stable protein 1                                             1.706     1.690
  IPI:IPI00926256.1   SLC4A1      Band 3 anion transport protein                                                      1.629     1.690
  IPI:IPI00010133.3   CORO1A      Coronin-1A                                                                          1.820     1.660
  IPI:IPI00021766.5   RTN4        Isoform 1 of Reticulon-4                                                            1.871     1.629
  IPI:IPI00218414.5   CA2         Carbonic anhydrase 2                                                                1.871     1.629
  IPI:IPI00916847.1   OLA1        OLA1 47 kDa protein                                                                 2.109     1.614
  IPI:IPI00186966.3   BIN1        Isoform IIA of Myc box-dependent-interacting protein 1                              1.803     1.585
  IPI:IPI00965262.1   CLASP2      166 kDa protein                                                                     1.754     1.585
  IPI:IPI00185159.7   BAIAP2      Isoform 4 of Brain-specific angiogenesis inhibitor 1-associated protein 2           1.614     1.528
  IPI:IPI00940222.1   AKAP12      Isoform 3 of A-kinase anchor protein 12                                             1.600     1.500
  IPI:IPI00479514.2   CACNA2D1    Isoform 2 of Voltage-dependent calcium channel subunit alpha-2/delta-1              1.675     1.486
  IPI:IPI00017895.3   GPD2        Isoform 1 of Glycerol-3-phosphate dehydrogenase, mitochondrial                      1.600     1.486
  IPI:IPI00385612.2   SLC8A2      Putative uncharacterized protein DKFZp761D171                                       1.514     1.486
  IPI:IPI00294187.1   PADI2       Protein-arginine deiminase type-2                                                   1.459     1.486
  IPI:IPI00455620.3   RUFY3       protein RUFY3 isoform 1                                                             1.445     1.486
  IPI:IPI00942902.1   GDA         Guanine deaminase                                                                   1.472     1.472
  IPI:IPI00022774.3   VCP         Transitional endoplasmic reticulum ATPase                                           2.965     1.459
  IPI:IPI00910602.1   NEFH        Isoform 1 of Neurofilament heavy polypeptide                                        1.614     1.445
  IPI:IPI00465436.4   CAT         Catalase                                                                            1.644     1.380
  IPI:IPI00159927.2   NCAN        Neurocan core protein                                                               1.675     1.330
  IPI:IPI00306667.5   CNP         Isoform CNPII of 2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase                    1.393     1.318
  IPI:IPI00456623.2   BCAN        Isoform 1 of Brevican core protein                                                  1.432     1.306

10.1371/journal.pone.0172214.t003

###### 89 down-regulated proteins in childhood cortical dysplasia patients with epilepsy compared to controls by iTRAQ.

![](pone.0172214.t003){#pone.0172214.t003g}

  Accession           Gene Name   Protein                                                                            118:117   121:119
  ------------------- ----------- ---------------------------------------------------------------------------------- --------- ---------
  IPI:IPI00480085.6   DNM3        Putative uncharacterized protein DNM3                                              0.711     0.738
  IPI:IPI00909720.1   PSD3        cDNA FLJ54694, highly similar to Pleckstrin and Sec7 domain-containing protein3    0.679     0.738
  IPI:IPI00219446.5   PEBP1       Phosphatidylethanolamine-binding protein 1                                         0.679     0.731
  IPI:IPI00418471.6   VIM         Vimentin                                                                           0.738     0.718
  IPI:IPI00789794.1   DLG4        disks large homolog 4 isoform 2                                                    0.731     0.711
  IPI:IPI00024990.6   ALDH6A1     Methylmalonate-semialdehyde dehydrogenase \[acylating\], mitochondrial             0.745     0.705
  IPI:IPI00011515.1   PACSIN1     Protein kinase C and casein kinase substrate in neurons protein 1                  0.745     0.698
  IPI:IPI00926312.1   OGDH        oxoglutarate dehydrogenase isoform 3 precursor                                     0.745     0.685
  IPI:IPI00031804.1   VDAC3       Isoform 1 of Voltage-dependent anion-selective channel protein 3                   0.698     0.685
  IPI:IPI00007682.2   ATP6V1A     V-type proton ATPase catalytic subunit A                                           0.766     0.673
  IPI:IPI00003968.1   NDUFA9      NADH dehydrogenase \[ubiquinone\] 1 alpha subcomplex subunit 9, mitochondrial      0.649     0.673
  IPI:IPI00217871.4   ALDH4A1     Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial                       0.759     0.667
  IPI:IPI00954954.1   CLU         clusterin isoform 3                                                                0.752     0.667
  IPI:IPI00299402.1   PC          Pyruvate carboxylase, mitochondrial                                                0.679     0.667
  IPI:IPI00007812.1   ATP6V1B2    V-type proton ATPase subunit B, brain isoform                                      0.711     0.661
  IPI:IPI00026216.4   NPEPPS      Puromycin-sensitive aminopeptidase                                                 0.673     0.655
  IPI:IPI00386271.4   SLC25A12    Calcium-binding mitochondrial carrier protein Aralar1                              0.698     0.649
  IPI:IPI00167215.6   HEPACAM     Isoform 1 of Hepatocyte cell adhesion molecule                                     0.619     0.637
  IPI:IPI00940744.1   NDUFS1      NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial                       0.608     0.637
  IPI:IPI00009439.1   SYT1        Synaptotagmin-1                                                                    0.738     0.625
  IPI:IPI00300568.4   SYN1        Isoform IA of Synapsin-1                                                           0.614     0.625
  IPI:IPI00017855.1   ACO2        Aconitate hydratase, mitochondrial                                                 0.711     0.608
  IPI:IPI00219078.5   ATP2A2      Isoform 1 of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2                   0.631     0.592
  IPI:IPI00847322.1   SOD2        superoxide dismutase 2, mitochondrial isoform A precursor                          0.766     0.586
  IPI:IPI00018342.5   AK1         Adenylate kinase isoenzyme 1                                                       0.679     0.575
  IPI:IPI00009532.5   ABAT        cDNA FLJ56034, highly similar to 4-aminobutyrate aminotransferase, mitochondrial   0.597     0.570
  IPI:IPI00218660.3   ITPR1       Isoform 4 of Inositol 1,4,5-trisphosphate receptor type 1                          0.470     0.570
  IPI:IPI00873201.1   PSAP        Isoform Sap-mu-6 of Proactivator polypeptide                                       0.457     0.565
  IPI:IPI00328156.9   MAOB        Amine oxidase \[flavin-containing\] B                                              0.619     0.555
  IPI:IPI00219219.3   LGALS1      Galectin-1                                                                         0.586     0.550
  IPI:IPI00746777.3   ADH5        Alcohol dehydrogenase class-3                                                      0.515     0.550
  IPI:IPI00016801.1   GLUD1       Glutamate dehydrogenase 1, mitochondrial                                           0.679     0.545
  IPI:IPI00941244.1   AQP4        33 kDa protein                                                                     0.673     0.545
  IPI:IPI00006663.1   ALDH2       Aldehyde dehydrogenase, mitochondrial                                              0.643     0.545
  IPI:IPI00028520.2   NDUFV1      Isoform 1 of NADH dehydrogenase \[ubiquinone\] flavoprotein 1, mitochondrial       0.565     0.545
  IPI:IPI00946334.1   NDUFS2      dehydrogenase (ubiquinone) Fe-S protein 2 isoform 2 precursor                      0.530     0.545
  IPI:IPI00643720.3   OGDHL       2-oxoglutarate dehydrogenase-like, mitochondrial                                   0.614     0.540
  IPI:IPI00023591.1   PURA        Transcriptional activator protein Pur-alpha                                        0.718     0.535
  IPI:IPI00009771.6   LMNB2       Lamin-B2                                                                           0.625     0.530
  IPI:IPI00015602.1   TOMM70A     Mitochondrial import receptor subunit TOM70                                        0.597     0.530
  IPI:IPI00011229.1   CTSD        Cathepsin D                                                                        0.575     0.530
  IPI:IPI00013508.5   ACTN1       Alpha-actinin-1                                                                    0.530     0.530
  IPI:IPI00021088.1   KCNAB2      Isoform 1 of Voltage-gated potassium channel subunit beta-2                        0.373     0.530
  IPI:IPI00383807.1   SLC4A4      Electrogenic Na+ bicarbonate cotransporter (Fragment)                              0.631     0.525
  IPI:IPI00479877.4   ALDH9A1     4-trimethylaminobutyraldehyde dehydrogenase                                        0.488     0.520
  IPI:IPI00413060.1   SYNPO       Isoform 3 of Synaptopodin                                                          0.461     0.520
  IPI:IPI00004358.4   PYGB        Glycogen phosphorylase, brain form                                                 0.685     0.515
  IPI:IPI00007087.4   FBXO2       F-box only protein 2                                                               0.501     0.511
  IPI:IPI00008485.1   ACO1        Cytoplasmic aconitate hydratase                                                    0.711     0.506
  IPI:IPI00411706.1   ESD         S-formylglutathione hydrolase                                                      0.479     0.501
  IPI:IPI00017704.3   COTL1       Coactosin-like protein                                                             0.466     0.501
  IPI:IPI00291175.7   VCL         Isoform 1 of Vinculin                                                              0.457     0.501
  IPI:IPI00025796.3   NDUFS3      NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 3, mitochondrial             0.540     0.497
  IPI:IPI00657774.1   STX1B       Syntaxin 1B alternative isoform deltaTM                                            0.631     0.492
  IPI:IPI00220271.3   AKR1A1      Alcohol dehydrogenase \[NADP+\]                                                    0.555     0.492
  IPI:IPI00006579.1   COX4I1      Cytochrome c oxidase subunit 4 isoform 1, mitochondrial                            0.511     0.488
  IPI:IPI00021812.2   AHNAK       Neuroblast differentiation-associated protein AHNAK                                0.565     0.483
  IPI:IPI00418169.3   ANXA2       Isoform 2 of Annexin A2                                                            0.413     0.453
  IPI:IPI00016077.1   GBAS        Protein NipSnap homolog 2                                                          0.550     0.441
  IPI:IPI00645031.1   CRYL1       Isoform 2 of Lambda-crystallin homolog                                             0.483     0.441
  IPI:IPI00301180.4   SLC12A5     Isoform 2 of Solute carrier family 12 member 5                                     0.479     0.441
  IPI:IPI00027497.5   GPI         Glucose-6-phosphate isomerase                                                      0.705     0.433
  IPI:IPI00872379.1   ANXA5       36 kDa protein                                                                     0.373     0.421
  IPI:IPI00010130.3   GLUL        Glutamine synthetase                                                               0.649     0.417
  IPI:IPI00514285.2   PTGDS       Prostaglandin D2 synthase 21kDa                                                    0.497     0.413
  IPI:IPI00946099.1   SRI         Putative uncharacterized protein SRI                                               0.328     0.409
  IPI:IPI00216138.6   TAGLN       Transgelin                                                                         0.302     0.409
  IPI:IPI00013043.1   TPPP        Tubulin polymerization-promoting protein                                           0.685     0.394
  IPI:IPI00219067.4   GSTM2       Glutathione S-transferase Mu 2                                                     0.497     0.391
  IPI:IPI00302592.2   FLNA        Isoform 2 of Filamin-A                                                             0.350     0.391
  IPI:IPI00005038.1   HRSP12      Ribonuclease UK114                                                                 0.406     0.387
  IPI:IPI00514424.4   PPT1        Palmitoyl-protein thioesterase 1                                                   0.394     0.377
  IPI:IPI00641737.1   HP          Haptoglobin                                                                        0.429     0.356
  IPI:IPI00303568.3   PTGES2      Prostaglandin E synthase 2                                                         0.429     0.356
  IPI:IPI00013698.3   ASAH1       N-acylsphingosine amidohydrolase (Acid ceramidase) 1, isoform CRA_c                0.433     0.353
  IPI:IPI00604710.2   SLC3A2      Isoform 1 of 4F2 cell-surface antigen heavy chain                                  0.488     0.347
  IPI:IPI00021828.1   CSTB        Cystatin-B                                                                         0.492     0.328
  IPI:IPI00002280.1   PCSK1N      ProSAAS                                                                            0.313     0.328
  IPI:IPI00413674.1   PHYHD1      Isoform 1 of Phytanoyl-CoA dioxygenase domain-containing protein 1                 0.511     0.302
  IPI:IPI00515081.4   IGSF1       Isoform 2 of Immunoglobulin superfamily member 1                                   0.366     0.296
  IPI:IPI00423460.3   IGHA1       Putative uncharacterized protein DKFZp686G21220 (Fragment)                         0.233     0.273
  IPI:IPI00218487.3   GJA1        Gap junction alpha-1 protein                                                       0.283     0.268
  IPI:IPI00022143.3   ESYT1       Isoform 1 of Extended synaptotagmin-1                                              0.384     0.265
  IPI:IPI00156689.3   VAT1        Synaptic vesicle membrane protein VAT-1 homolog                                    0.360     0.238
  IPI:IPI00011200.5   PHGDH       D-3-phosphoglycerate dehydrogenase                                                 0.261     0.217
  IPI:IPI00027442.4   AARS        Alanyl-tRNA synthetase, cytoplasmic                                                0.437     0.209
  IPI:IPI00010800.2   NES         Nestin                                                                             0.077     0.099
  IPI:IPI00001734.3   PSAT1       Phosphoserine aminotransferase                                                     0.067     0.086
  IPI:IPI00220301.5   PRDX6       Peroxiredoxin-6                                                                    0.078     0.082

Using PANTHER classification system, the 153 proteins were divided into 9 functional categories including catalytic activity (38.0%), binding (26.3%), molecule-structuring activity (14.0%), transporter activity (8.8%), and enzyme regulation activity (5.3%) ([Fig 1](#pone.0172214.g001){ref-type="fig"}). 8 differentially expressed proteins, including FSCN1, CRMP1, NDRG1, DPYSL5, MAP4, FABP3, PRDX6 and PSAP were selected for further validation. The gene oncology terms of these 8 proteins were shown in [S1 Table](#pone.0172214.s001){ref-type="supplementary-material"}.

![Molecule functional categories of 153 differentially exprssed proteins using the PANTHER Classification System.](pone.0172214.g001){#pone.0172214.g001}

qPCR in children having CCD with epilepsy {#sec014}
-----------------------------------------

The levels of mRNA expression for fascin actin-bundling protein 1 (FSCN1), collapsin response mediator protein 1 (CRMP1), N-myc downstream regulated 1 (NDRG1), dihydropyrimidinase-related protein 5 (DPYSL5), peroxiredoxin 6 (PRDX6), prosaposin (PSAP), microtubule associated protein 4 (MAP4), and fatty acid binding protein 3 (FABP3) are presented in [Fig 2](#pone.0172214.g002){ref-type="fig"}. The expression of FSCN1, CRMP1, NDRG1, DPYSL5, MAP4, and FABP3 were found to be up-regulated in the CCD patients (Relative mRNA expression: CRMP1, 2.21±0.12; NDRG1, 3.61±0.11; DPYSL5, 2.73±0.12; MAP4, 3.17±0.08; FAPB3, 2.88±0.06. p\<0.05 for each mRNA expression compared to controls), and the expression of PRDX6 and PSAP were down-regulated (Relative mRNA expression: PRDX6, 0.35±0.14; PSAP, 0.24±0.06. p\<0.05 for both mRNA expression compared to controls) compared to controls.

![Relative mRNA expression levels of NDRG1, FSCN1, FABP3, DPYSL5, PSAP, MAP4, CRMP1, PRDX6.\
\*p\<0.05 compared to controls.](pone.0172214.g002){#pone.0172214.g002}

Immunoblotting {#sec015}
--------------

CRMP1, DPYSL5, FSCN1, NDRG1, PRDX6 were further validated with immunoblotting. In CCD patients, the protein levels of CRMP1 (CCD group: 1.31±0.35; Controls: 0.41±0.15. p\<0.05), DPYSL5 (CCD group: 1.04±0.07; Controls: 0.11±0.03. p\<0.05), FSCN1 (CCD group: 1.89±0.18; Controls: 1.02±0.17. p\<0.05) and NDRG1 (CCD group: 0.38±0.04; Controls: 0.04±0.01. p\<0.05) were increased, while the protein level of PRDX6 (CCD group: 0.34±0.06; Controls: 2.00±0.37. p\<0.05) was decreased compared to controls ([Fig 3](#pone.0172214.g003){ref-type="fig"}).

![Immunoblotting for CRMP1, DPYSL5, NDRG1, FSCN1 and PRDX6.\
Quantification of protein levels showed increased expression of CRMP1 (A), DPYSL5 (B), NDRG1 (C) and FSCN1 (D) and decreased expression of PRDX6 (E) in brain tissue of childhood cortical dysplasia patients compared to controls. \*p\<0.05 compared to controls.](pone.0172214.g003){#pone.0172214.g003}

Immunohistochemistry {#sec016}
--------------------

The expression of DPYSL5, CRMP1 and FSCN1 were further measured by IHC. There were increased immunoreactivity of CRMP1 (Scores: CCD group: 95.50±25.52; Controls: 15.76±5.28. p\<0.05) ([Fig 4](#pone.0172214.g004){ref-type="fig"}), DPYSL5 (Scores: CCD group: 90.93±13.15; Controls: 29.33±5.21. p\<0.05) ([Fig 4](#pone.0172214.g004){ref-type="fig"}), and FSCN1 (Scores: CCD group: 126.53±30.70; Controls: 15.06±3.45. p\<0.05) ([Fig 4](#pone.0172214.g004){ref-type="fig"}) in the CDD group compared to controls.

![Immunohistochemistry of CRMP1, DPYSL5 and FSCN1.\
IHC score of CRMP1 (A & B), DPYSL5 (C & D) and FSCN1 (E & F) were significantly increased in brain tissues of childhood cortical dysplasia patients with epilepsy compared to controls. \*p\<0.05 compared to controls.](pone.0172214.g004){#pone.0172214.g004}

Discussion {#sec017}
==========

In our study, 153 proteins were identified differentially expressed in brain tissues of CCD patients with epilepsy compared to controls using iTRAQ. According to the functional classification using PANTHER, the 153 differentially expressed proteins were divided into 9 categories, which were involved in activities of various biological process, including catalytic activity (38.0%), binding (26.3%), molecule-structuring activity (14.0%), transporter activity (8.8%), and enzyme regulation activity (5.3%).

Among the 153 proteins, the expression of FSCN1, CRMP1, NDRG1, DPYSL5, MAP4 and FABP3 was increased in the CCD patients compared to controls, while the expression of PRDX6 and PSAP was decreased in iTRAQ analysis. And these results were validated by real-time PCR, immunoblotting and immunohistochemistry.

FSCN1 is an actin-binding protein and can affect the formation and maintenance of cytoskeleton structure \[[@pone.0172214.ref022]\]. FSCN1 increases in neurogenesis and can help neurites maintain their normal shape, and it is considered as a candidate gene for developmental brain disorders \[[@pone.0172214.ref023], [@pone.0172214.ref024]\]. FSCN1-related pathways mainly participate in the migration of neurons, which was known as a key mechanism of cortical dysplasia \[[@pone.0172214.ref025]\]. So it is possible that, in our study, the increased level of FSCN1 indicates an abnormally enhanced neurogenesis, neurite outgrowth and neuronal migration, and thus, result in CCD and epilepsy. However, the effect of increased FSCN1 on neurons needs to be further researched.

Collapsin response mediator protein 1 (CRMP1) belongs to the collapsing response mediator protein family (CRMPs) which is involved in the Sema-3A signaling pathway \[[@pone.0172214.ref026]--[@pone.0172214.ref028]\], CRMP1 also regulates migration, neurite outgrouwth, and dendrite orientation of neurons, its loss can retard the radial migration and neurite outgrowth of neurons and lead to abnormal orientation of basal dendrites of neurons \[[@pone.0172214.ref029]--[@pone.0172214.ref031]\]. Similar to FSCN1, the increased level of CRMP may also possibly indicate an abnormally enhanced neuron migration and neurite outgrowth and abnormal orientation of dendrites, which may have roles in CCD. Interestingly, in temporal lobe epilepsy (TLE) patients and animal models, decreased CRMP1 expression was reported \[[@pone.0172214.ref032]\]. It is possible that CRMP1 plays different roles in CCD with epilepsy and TLE. The specific role of CRMP1 in CCD with epilepsy needs further evaluation.

NDRG1 is upregulated during cell differentiation, and its cellular distribution and molecular assembly changes with postnatal development, which is correlated with the maturation of brain \[[@pone.0172214.ref033]\]. NDRG1 exists in oligodendrocytes in cerebrum and decreases significantly at the end stage of myelin degradation \[[@pone.0172214.ref034], [@pone.0172214.ref035]\], and its mutation is found related to subcortical white matter abnormalities and severe demyelinating neuropathy \[[@pone.0172214.ref036]\]. Interestingly, in patients with cortical dysplasia, the change of oligodendrocytes and oligodendrocyte precursor cells is conflicting in previous reports \[[@pone.0172214.ref037], [@pone.0172214.ref038]\], and some patients with malformation of cortical development have reactive oligodendroglial hyperplasia \[[@pone.0172214.ref037]\]. These suggest complicated roles of oligodendrocytes and myelin sheath in cortical dysplasia. In our study, we found NDRG1 abnormally increased in CCD patients, which may suggest a possible mechanism of reactive oligodendroglial hyperplasia in CCD. However, whether NDRG1-mediated oligodendroglial change participate in the pathogenensis of CCD needs to be further illustrated.

Increased expression of DPYSL5 can regulate dendritic development by mediating BDNF signaling in the central nervous system and modulate the function of CRMP2 by interacting with tubulin \[[@pone.0172214.ref039], [@pone.0172214.ref040]\], thus affect the cytoskeleton remodeling, which is important in CCD with epilepsy. It has been reproted that BDNF, a neurotrophin, plays an important role in dendritic arborzation and synaptic neurotransmission \[[@pone.0172214.ref041]--[@pone.0172214.ref043]\], and CRMP2, a signaling molecule of Semaphoring-3A and a repulsive guidance cue, can induce growth cone collapse and regulate neuronal polarity \[[@pone.0172214.ref028]\], axon elongation and multiple axon formation \[[@pone.0172214.ref044], [@pone.0172214.ref045]\]. These suggest that DPYSL5 may function in CCD with epilepsy via affecting BDNF and CRMP2.

MAP4 exists in brain and many other organs, one of its isoforms was found neural cell specific and it can inhibit the movement of the microtubules in a concentration-dependent manner and reduce microtubule-stabilizing activity \[[@pone.0172214.ref046]--[@pone.0172214.ref048]\]. MAP4 is also known associated with epilepsy \[[@pone.0172214.ref049]\]. Notably, microtubule-associated proteins were known important in regulating neuronal migration and brain development \[[@pone.0172214.ref050]\]. Defects of neuronal migration can lead to cortical malformation and consequently cause severe intellectual disability and refractory epilepsy \[[@pone.0172214.ref051]\]. Therefore, the increase of MAP4, as in our study, may inhibit the movement and activity of microtubles and thus impair neuronal migration which participate in CCD.

FABP3 is considered as a promising and sensitive marker for minor brian injury and Creutzfeldt-Jakob disease \[[@pone.0172214.ref052], [@pone.0172214.ref053]\]. FABP3 expression is very low in neonatal brains and gradually increases after birth until adulthood, its expression pattern is correlated with synaptogenesis, myelinogenesis, neurite formation and synapse maturation \[[@pone.0172214.ref054]\]. FABP3 regulate the incorporation of arachidonic acid into brain, and may also regulate gene expression via controlling the availability of fatty acid ligands required for PPAR and RXR activity \[[@pone.0172214.ref054]\]. In our study, a increased FABP3 level was found in CCD patients, possibly indicating early maturity of metabolism pattern in CCD patients, which may contribute to the formation of cortical dysplasia. Moreover, FABP3 deficiency in mice showed protective effect against experimental autoimmune encephalomyelitis \[[@pone.0172214.ref055]\], indicating a possible role of autoimmune inflammation in CCD.

PRDX6 is an antioxidant protein which mainly exists in glia and keeps increasing as growing, it may have important roles in alzheimer's disease and parkinson's disease \[[@pone.0172214.ref056], [@pone.0172214.ref057]\]. PRDX6 can clear reactive oxygen species, regulate gene expression in brain and protect against oxidative stress-induced neuronal death \[[@pone.0172214.ref058]\]. Whether the reduction of PRDX6 in CCD patients is causal or consequential factor of CCD remains to be further illustrated. It is possible that, reduction of PRDX6 is a result of enhanced oxidative stress, which has been reported in previous study \[[@pone.0172214.ref058]\]. However, it is also possible that reduction of PRDX6 may contribute to the pathogenesis of CCD, because oxidative stress has been associated with developmental brain disorders and epileptogenesis, although the specific role of oxidative stress in the pathogenesis of cortical dysplasia remains to be illustrated \[[@pone.0172214.ref059], [@pone.0172214.ref060]\].

PSAP is precursor of saposin and acts as a lysosomal protein and a potent secreted neurotrophic factor, its temporal pattern of expression in perinatal brain indicate its potential role in brain development \[[@pone.0172214.ref061]\]. Infants with PSAP deficiency presented multifocal myoclonus and cyanotic hypoxemia immediately after birth, grand-mal epilepsy in the following days, and cortical and white matter morphogenetic disorders \[[@pone.0172214.ref062], [@pone.0172214.ref063]\]. This deficiency is considered to cause such manifestations via impairing the lipid storage\[[@pone.0172214.ref062], [@pone.0172214.ref063]\]. Therefore, abnormally reduction of PSAP in CCD patients may indicate a possible role of PSAP in the pathogenesis of CCD. Moreover, in kainate-induced epilepsy models, PSAP reactively increases and protects against the neurotoxicity \[[@pone.0172214.ref064]\]. Thus, PSAP reduction in CCD may also participate in the neuronal damage in CCD.

In conclusion, we identified 153 differentially expressed proteins in CCD patients compared to controls. Among these proteins, FSCN1, CRMP1, NDRG1, DPYSL5, MAP4, FABP3, PRDX6 and PSAP were further validated. These proteins have not been related to CCD before. Mechanisms including neuronal migration, neurite growth, cytoskeleton remodeling, inflammation, oligodendroglia hyperplasia, metabolic pattern and lipid storage may be involved in CCD pathogenesis and/or pathophysiology via these proteins, providing potential targets and directions for future researches on cortical dysplasia. Our study also indicate a complicated pathogenetic background of CCD, as these differentially expressed proteins have various cellular distribution and function. Moreover, further study is needed to illustrate the specific effects of these differentially expressed proteins on CCD with epilepsy, considering the limited sample size due to the critical criteria of surgery in CCD patients, especially in children.
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